Congenital myasthenic syndromes: multiple molecular targets at the neuromuscular junction.

@article{Engel2003CongenitalMS,
  title={Congenital myasthenic syndromes: multiple molecular targets at the neuromuscular junction.},
  author={Andrew G. Engel and Kinji Ohno and Xin-Ming Shen and Steven M. Sine},
  journal={Annals of the New York Academy of Sciences},
  year={2003},
  volume={998},
  pages={
          138-60
        }
}
Congenital myasthenic syndromes (CMS) stem from defects in presynaptic, synaptic, and postsynaptic proteins. The presynaptic CMS are associated with defects that curtail the evoked release of acetylcholine (ACh) quanta or ACh resynthesis. Defects in ACh resynthesis have now been traced to mutations in choline acetyltransferase. A synaptic CMS is caused by mutations in the collagenic tail subunit (ColQ) of the endplate species of acetylcholinesterase that prevent the tail subunit from… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Motor endplate remodeling in some cases with congenital myasthenic syndrome.

  • Folia neuropathologica
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Channelopathies: a review.

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Molecular control of neuromuscular junction development

  • Journal of cachexia, sarcopenia and muscle
  • 2012
VIEW 1 EXCERPT
CITES BACKGROUND

Skeletal Muscle Na+ Channel Disorders

  • Front. Pharmacol.
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND